Back to Search Start Over

Release Enhancement by Plasticizer Inclusion for Amorphous Solid Dispersions Containing High T g Drugs.

Authors :
Correa-Soto CE
Gao Y
Indulkar AS
Zhang GGZ
Taylor LS
Source :
Pharmaceutical research [Pharm Res] 2023 Mar; Vol. 40 (3), pp. 777-790. Date of Electronic Publication: 2023 Mar 01.
Publication Year :
2023

Abstract

Purpose: Plasticizers are commonly used in the preparation of amorphous solid dispersions (ASDs) with the main goal of aiding processability; however, to the best of our knowledge, the impact of plasticizers on drug release has not been explored. The goal of this study was to evaluate diverse plasticizers, including glycerol and citrate derivatives, as additives to increase the drug loading where good drug release could be achieved from copovidone (PVPVA)-based dispersions, focusing on high glass transition (T <subscript>g</subscript> ) drugs, atazanavir (ATZ) and ledipasvir (LED).<br />Methods: ASDs were prepared using the high T <subscript>g</subscript> compounds, atazanavir (ATZ) and ledipasvir (LED), as model drugs. Release was evaluated using surface normalized dissolution testing. Differential scanning calorimetry was used to measure glass transition temperature and water vapor sorption was performed on select samples.<br />Results: The presence of a plasticizer at 5% w/w for ATZ and 10% w/w for LED ASDs, led to improved drug release. For ATZ ASDs, in the absence of plasticizer, release was very poor at drug loadings of 10% w/w and above. Good release was obtained for plasticized ASDs up to a drug loading of 25%. The corresponding improvement for LED was from 5 to 20% DL. Interestingly, for a low T <subscript>g</subscript> compound, ritonavir, relatively smaller improvements in release as a function of drug loading were achieved through plasticizer incorporation.<br />Conclusions: The use of plasticizers represents a potential new strategy to increase drug loading in ASDs for high T <subscript>g</subscript> compounds with a low tendency to crystallize and may help improve a major limitation of ASD formulations, namely the high excipient burden.<br /> (© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)

Details

Language :
English
ISSN :
1573-904X
Volume :
40
Issue :
3
Database :
MEDLINE
Journal :
Pharmaceutical research
Publication Type :
Academic Journal
Accession number :
36859747
Full Text :
https://doi.org/10.1007/s11095-023-03483-3